Autoimmune diseases represent one of the major challenges of modern medicine. In these conditions, the immune system loses the ability to distinguish self from non-self, generating a chronic inflammatory response directed against the body’s own tissues.
In recent years, research in psychoneuroendocrinoimmunology (PNEI) has shown that these processes do not depend exclusively on the immune system, but also involve deep interactions with the nervous and endocrine systems. A recent observational clinical study explored this integrated perspective by evaluating the effectiveness of a neuroimmune therapy in patients with refractory autoimmune diseases who were unresponsive to conventional treatments.
The Role of the Neuro-Immune-Endocrine Axis
According to the study authors, many autoimmune diseases appear to be associated with dysregulation of the Th17/Treg axis, one of the key systems involved in immune balance and inflammatory control.
In this context, several neuroendocrine systems with immunomodulatory and anti-inflammatory functions become particularly relevant:
- melatonin produced by the pineal gland;
- the endocannabinoid system;
- the ACE2 / angiotensin 1-7 axis.
Experimental evidence suggests that these systems may modulate interleukin-17 (IL-17) signaling, one of the cytokines most strongly involved in autoimmune inflammatory processes.
The Clinical Study
The study involved 70 patients with refractory autoimmune diseases, meaning patients who either did not respond to or declined conventional immunosuppressive therapies.
The neuroimmune protocol included:
- oral melatonin (10–50 mg nightly);
- gastro-protected angiotensin 1-7;
- cannabidiol (CBD).
Researchers monitored:
- autoantibody levels;
- inflammatory biomarkers;
- clinical and radiological disease stability.
Observed Results
After three months of treatment, significant findings emerged.
Patients with Hashimoto’s thyroiditis showed a 49% reduction in anti-thyroglobulin antibodies, while patients with other systemic autoimmune diseases exhibited a 60% decrease in antinuclear antibody titers.
Particularly noteworthy were the findings related to multiple sclerosis: 62% of patients achieved radiological disease stabilization during follow-up.
The lymphocyte-to-monocyte ratio (LMR), considered a marker of systemic inflammation, also improved in most patients experiencing disease flares at enrollment.
Furthermore, the treatment was well tolerated, with no clinically significant adverse events reported.
An Integrated Perspective for Chronic Diseases
Perhaps the most innovative aspect of this study lies in the paradigm it proposes. The neuroimmune approach does not simply aim to suppress symptoms or block inflammation; instead, it seeks to support the biological systems that regulate the body’s balance.
This perspective is fully consistent with PNEI: the brain, immune system, and endocrine system are not isolated structures, but interconnected parts of a dynamic network in constant communication.
The authors themselves emphasize the need for further randomized controlled trials to confirm these findings. Nevertheless, the direction of research appears increasingly clear: understanding and modulating communication among biological systems may become one of the fundamental challenges of the medicine of the future.